Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
25 03 2022
Historique:
received: 23 06 2021
accepted: 04 03 2022
entrez: 26 3 2022
pubmed: 27 3 2022
medline: 14 4 2022
Statut: epublish

Résumé

Loss of expression or activity of the tumor suppressor PTEN acts similarly to an activating mutation in the oncogene PIK3CA in elevating intracellular levels of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), inducing signaling by AKT and other pro-tumorigenic signaling proteins. Here, we analyze sequence data for 34,129 colorectal cancer (CRC) patients, capturing 3,434 PTEN mutations. We identify specific patterns of PTEN mutation associated with microsatellite stability/instability (MSS/MSI), tumor mutational burden (TMB), patient age, and tumor location. Within groups separated by MSS/MSI status, this identifies distinct profiles of nucleotide hotspots, and suggests differing profiles of protein-damaging effects of mutations. Moreover, discrete categories of PTEN mutations display non-identical patterns of co-occurrence with mutations in other genes important in CRC pathogenesis, including KRAS, APC, TP53, and PIK3CA. These data provide context for clinical targeting of proteins upstream and downstream of PTEN in distinct CRC cohorts.

Identifiants

pubmed: 35338148
doi: 10.1038/s41467-022-29227-2
pii: 10.1038/s41467-022-29227-2
pmc: PMC8956741
doi:

Substances chimiques

Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PTEN Phosphohydrolase EC 3.1.3.67
PTEN protein, human EC 3.1.3.67

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1618

Subventions

Organisme : NIGMS NIH HHS
ID : F30 GM142263
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK108195
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA256234
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Nat Genet. 2015 Dec;47(12):1402-7
pubmed: 26551669
Cell. 1999 Oct 29;99(3):323-34
pubmed: 10555148
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancers (Basel). 2019 Nov 09;11(11):
pubmed: 31717544
Eur J Hum Genet. 2020 Oct;28(10):1387-1393
pubmed: 32533092
Cancer Discov. 2017 Jun;7(6):610-619
pubmed: 28363909
Cell. 1998 Oct 2;95(1):29-39
pubmed: 9778245
BMC Cancer. 2011 Apr 07;11:123
pubmed: 21473780
Cancer Cell. 2019 Mar 18;35(3):504-518.e7
pubmed: 30827889
Proteins. 2016 Nov;84(11):1625-1643
pubmed: 27481051
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Annu Rev Pathol. 2009;4:127-50
pubmed: 18767981
World J Gastroenterol. 2015 May 7;21(17):5167-75
pubmed: 25954090
Cancer Res. 2020 Jul 1;80(13):2775-2789
pubmed: 32366478
Transl Oncol. 2018 Oct;11(5):1188-1201
pubmed: 30071442
Am J Hum Genet. 2019 May 2;104(5):861-878
pubmed: 31006514
Methods Mol Biol. 2016;1418:111-41
pubmed: 27008012
J Biomol Struct Dyn. 2019 Apr;37(7):1766-1782
pubmed: 29663862
Cancer Res. 2008 Mar 15;68(6):1953-61
pubmed: 18339877
J Clin Oncol. 2005 Jan 20;23(3):609-18
pubmed: 15659508
Int J Mol Sci. 2019 Sep 19;20(18):
pubmed: 31546890
Biomolecules. 2019 Nov 07;9(11):
pubmed: 31703360
Mol Biol Evol. 2021 Jul 29;38(8):3235-3246
pubmed: 33779753
Nature. 2015 Nov 5;527(7576):100-104
pubmed: 26479035
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Nat Cell Biol. 2011 Jun;13(6):728-33
pubmed: 21532586
Oncogene. 2010 Feb 4;29(5):687-97
pubmed: 19915616
Nature. 2017 Feb 23;542(7642):484-488
pubmed: 28166537
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Cold Spring Harb Perspect Med. 2020 Sep 1;10(9):
pubmed: 31932469
Hum Mutat. 2019 Sep;40(9):1495-1506
pubmed: 31184403
Oncologist. 2013;18(10):1083-90
pubmed: 24037976
Cancer Res. 2004 May 1;64(9):3014-21
pubmed: 15126336
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Clin Colorectal Cancer. 2015 Dec;14(4):203-18
pubmed: 26077270
Leukemia. 2007 Nov;21(11):2368-70
pubmed: 17657213
Hum Mutat. 2008 Nov;29(11):E252-62
pubmed: 18781614
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Nat Cancer. 2020 Apr;1(4):382-393
pubmed: 32864625
Hum Mutat. 2016 Jun;37(6):564-9
pubmed: 26931183
Cold Spring Harb Perspect Med. 2020 Apr 1;10(4):
pubmed: 31570378
Trends Cancer. 2017 Oct;3(10):686-697
pubmed: 28958387
Am J Hum Genet. 2018 May 3;102(5):943-955
pubmed: 29706350
Oncogene. 2008 Sep 18;27(41):5497-510
pubmed: 18794884
Am J Hum Genet. 2020 Jun 4;106(6):818-829
pubmed: 32442409
Cancer Res. 2006 Apr 15;66(8):3992-5
pubmed: 16618717
Cancer Cell. 2018 Apr 9;33(4):721-735.e8
pubmed: 29622466
Science. 2013 Jul 26;341(6144):395-9
pubmed: 23888040
Structure. 2015 Oct 6;23(10):1952-1957
pubmed: 26299948
J Natl Cancer Inst. 2015 Feb 24;107(3):
pubmed: 25713148
Genome Res. 2018 May;28(5):666-675
pubmed: 29636374
Clin Cancer Res. 2012 Jan 15;18(2):400-7
pubmed: 22252256
Neoplasia. 2018 Sep;20(9):943-950
pubmed: 30121009
Hum Mutat. 2018 Nov;39(11):1581-1592
pubmed: 30311380
Gastroenterology. 2010 Dec;139(6):1927-33
pubmed: 20600018
Nat Commun. 2019 Aug 19;10(1):3722
pubmed: 31427573
Int J Cancer. 2019 Jan 15;144(2):389-401
pubmed: 29978469
Gastroenterology. 2016 Sep;151(3):440-447.e1
pubmed: 27302833
Nature. 2015 Feb 12;518(7538):240-4
pubmed: 25409150
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Science. 2004 Feb 20;303(5661):1179-81
pubmed: 14976311
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Genet. 2010 May;42(5):454-8
pubmed: 20400965
Genome Med. 2017 Jan 23;9(1):4
pubmed: 28115009
Annu Rev Med. 2016;67:11-28
pubmed: 26473415
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216
pubmed: 28404093
Hum Mol Genet. 2002 Feb 15;11(4):445-50
pubmed: 11854177
Cell Chem Biol. 2018 Jan 18;25(1):19-29
pubmed: 29153852
Am J Pathol. 2002 Aug;161(2):439-47
pubmed: 12163369
Trends Biochem Sci. 2014 Apr;39(4):183-90
pubmed: 24656806
Nat Commun. 2016 Jun 15;7:11743
pubmed: 27302369
J Cell Biochem. 2018 Mar;119(3):2460-2469
pubmed: 28230287
Annu Rev Med. 2020 Jan 27;71:103-116
pubmed: 31433956
Nat Commun. 2020 Apr 29;11(1):2073
pubmed: 32350270
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Lancet Oncol. 2011 Jun;12(6):594-603
pubmed: 21163703
Cancer Res. 1998 Dec 15;58(24):5667-72
pubmed: 9865719
Semin Cancer Biol. 2019 Dec;59:66-79
pubmed: 30738865
N Engl J Med. 2012 Oct 25;367(17):1596-606
pubmed: 23094721
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Hum Genomics. 2016 Jan 16;10:4
pubmed: 26772741
Cell Rep. 2016 Apr 26;15(4):857-865
pubmed: 27149842
Int J Cancer. 2013 Nov;133(9):2089-101
pubmed: 23629727
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Front Oncol. 2014 Jan 16;3:326
pubmed: 24475377
Dis Colon Rectum. 2010 Jan;53(1):57-64
pubmed: 20010352
Cold Spring Harb Perspect Med. 2019 Nov 1;9(11):
pubmed: 31451538
Hum Mol Genet. 2011 Nov 1;20(21):4132-42
pubmed: 21828076
Cancer Cell. 2018 Jan 8;33(1):125-136.e3
pubmed: 29316426
Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562
pubmed: 29858604
J Exp Clin Cancer Res. 2019 Jan 28;38(1):41
pubmed: 30691487
Nat Commun. 2022 Mar 25;13(1):1618
pubmed: 35338148
Nat Genet. 2018 Jun;50(6):874-882
pubmed: 29785012
Cancer Discov. 2018 Feb;8(2):174-183
pubmed: 29247016
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669

Auteurs

Ilya G Serebriiskii (IG)

Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. Ilya.Serebriiskii@fccc.edu.
Kazan Federal University, Russian Federation, 420000, Kazan, Russia. Ilya.Serebriiskii@fccc.edu.

Valery Pavlov (V)

Kazan Federal University, Russian Federation, 420000, Kazan, Russia.
Moscow Institute of Physics and Technology, Russian Federation, 141701, Dolgoprudny, Moscow Region, Russia.

Rossella Tricarico (R)

Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Department of Biology and Biotechnology, University of Pavia, 27100, Pavia, Italy.

Grigorii Andrianov (G)

Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Kazan Federal University, Russian Federation, 420000, Kazan, Russia.

Emmanuelle Nicolas (E)

Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.

Mitchell I Parker (MI)

Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Molecular & Cell Biology & Genetics (MCBG) Program, Drexel University College of Medicine, 19102, Philadelphia, PA, USA.

Justin Newberg (J)

Foundation Medicine Inc, 150 Second St., Cambridge, MA, 02141, USA.

Garrett Frampton (G)

Foundation Medicine Inc, 150 Second St., Cambridge, MA, 02141, USA.

Joshua E Meyer (JE)

Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.

Erica A Golemis (EA)

Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. Erica.Golemis@fccc.edu.
Department of Cancer and Cellular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA. Erica.Golemis@fccc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH